Search

Recursion Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

3.24 -7.16

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.22

Maximum

3.49

Fő mutatók

By Trading Economics

Bevétel

-14M

-131M

Értékesítés

1.2M

7.7M

Egy részvényre jutó nyereség

-0.25

Profit margin

-1,708.018

Munkavállalók

600

EBITDA

-10M

-113M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+83.71% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-20M

1.7B

Előző nyitás

10.4

Előző zárás

3.24

Recursion Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

2026. aug. 21. 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

2026. aug. 20. 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

2026. aug. 19. 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

2026. aug. 18. 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

2026. aug. 17. 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

2026. aug. 12. 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

2026. aug. 11. 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

2026. aug. 10. 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

2026. aug. 7. 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

2026. aug. 6. 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

2026. aug. 5. 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

2026. aug. 4. 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

2026. aug. 3. 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

2026. júl. 31. 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

2026. júl. 30. 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

2026. júl. 29. 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

2026. júl. 28. 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

2026. júl. 27. 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

2026. júl. 24. 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

2026. júl. 23. 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

2026. júl. 22. 23:36 UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

2026. júl. 21. 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

2026. júl. 20. 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Társak összehasonlítása

Árváltozás

Recursion Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

83.71% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 6.43 USD  83.71%

Magas 8 USD

Alacsony 5.3 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Recursion Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

4 ratings

1

Vétel

3

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat